View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, May 21 (HealthDay News) -- The prostaglandin analogue misoprostol, when added to standard uterotonic therapy, does not result in decreased postpartum blood loss, according to research published in the May 22 issue of The Lancet.
Mariana Widmer, M.Sc., of the World Health Organization, Geneva, Switzerland, and colleagues conducted a randomized double-blind, multicenter international study of 1,422 women diagnosed with postpartum hemorrhage due to uterine atony. In the intervention arm of the study, the women received 600 micrograms of misoprostol, sublingually, in addition to the standard therapy of uterotonics. This group was compared to the control group of women who received only the standard uterotonic therapy.
The misoprostol group and the standard therapy group had the same proportion of women (14 percent) with blood loss of 500 mL or greater within 60 minutes. A higher proportion of women in the misoprostol group versus the standard therapy group had shivering (65 percent and 32 percent, respectively) and body temperature of 38 degrees Celsius (100.4 F) or greater (43 percent and 15 percent, respectively).
"The findings of this trial do not support the use of misoprostol in addition to other conventional uterotonics for the treatment of atonic postpartum hemorrhage. Any further research on misoprostol should focus on the possible effectiveness of misoprostol in settings where standard uterotonics are not available," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top